Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study

Atherosclerosis

Volumn 205, Issue 1, 2009, Pages 233-238

  Zhang, Mary H ^a   Spies, Christian ^b   Ali, Sadia ^c   Kanaya, Alka M ^d   Schiller, Nelson B ^d   Whooley, Mary A ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipokine; Adiponectin; Coronary heart disease (CHD); Ischemia; Reverse epidemiology

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; RISK ASSESSMENT; STRESS ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADIPONECTIN; AGED; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTPATIENTS; TREATMENT OUTCOME;

EID: 67349280629     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.11.014     Document Type: Article

References (34)

1. Havel P.J. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13 (2002) 51-59
2. Ouchi N., Shibata R., and Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med 16 (2006) 141-146
3. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
4. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278 (2003) 2461-2468
5. Tian L., Luo N., Klein R.L., et al. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis (2008) 10.1016/j.atherosclerosis.2008.04.011
6. Vaverkova H., Karasek D., Novotny D., et al. Positive association of adiponectin with soluble vascular cell adhesion molecule sVCAM-1 levels in patients with vascular disease or dyslipidemia. Atherosclerosis 197 (2008) 725-731
7. Shibata R., Sato K., Pimentel D.R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 (2005) 1096-1103
8. Tao L., Gao E., Jiao X., et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115 (2007) 1408-1416
9. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
10. Maahs D.M., Ogden L.G., Kinney G.L., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111 (2005) 747-753
11. Wolk R., Berger P., Lennon R.J., et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 28 (2007) 292-298
12. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
13. Lawlor D.A., Davey Smith G., Ebrahim S., et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90 (2005) 5677-5683
14. Steffes M.W., Gross M.D., Lee D.H., et al. Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the Coronary Artery Risk Development in Young Adults Study. Obesity (Silver Spring) 14 (2006) 319-326
15. Cavusoglu E., Ruwende C., Chopra V., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27 (2006) 2300-2309
16. Dekker J.M., Funahashi T., Nijpels G., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 93 (2008) 1489-1496
17. Beattie M.S., Shlipak M.G., Liu H., et al. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. Circulation 107 (2003) 245-250
18. Bibbins-Domingo K., Gupta R., Na B., et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297 (2007) 169-176
19. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 106 (2002) 1883-1892
20. Bibbins-Domingo K., Ansari M., Schiller N.B., et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 108 (2003) 2987-2992
21. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
22. Gehi A.K., Ali S., Na B., et al. Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study. Arch Intern Med 168 (2008) 1423-1428
23. Rathmann W., and Herder C. Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology". Horm Metab Res 39 (2007) 1-2
24. Soydinc S., Davutoglu V., and Sari I. High serum levels of adiponectin improve coronary collateral development in patients with coronary artery disease. Tohoku J Exp Med 211 (2007) 347-352
25. Tsuchida A., Yamauchi T., Ito Y., et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279 (2004) 30817-30822
26. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
27. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
28. Mallamaci F., Zoccali C., Cuzzola F., et al. Adiponectin in essential hypertension. J Nephrol 15 (2002) 507-511
29. Risch L., Saely C., Hoefle G., et al. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin Chim Acta 376 (2007) 108-113
30. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
31. Sattar N., Watt P., Cherry L., et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J Clin Endocrinol Metab 93 (2008) 1846-1849
32. Zyriax B.C., Algenstaedt P., Hess U.F., et al. Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study. Atherosclerosis 200 (2008) 403-409
33. Rathmann W., Haastert B., Herder C., et al. Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes (Lond) 31 (2007) 770-776
34. von Eynatten M., Humpert P.M., Bluemm A., et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 199 (2008) 123-128